A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2001
10/24/2001	CN1319093A Aminoalkyl-3,4-dihydroquindine derivates as No-synthase inhibitors
10/24/2001	CN1319092A Benzamide derivatives and their use as cytokine inhibitors
10/24/2001	CN1319021A Chemokine receptor antagonist and ocyclosporin in combined therapy
10/24/2001	CN1319019A i(ex vivo) treatment of allogeneic and xanogeneic T-cells with gp39 antagonists
10/24/2001	CN1318312A Radix Acanthopanacis senticosi tea
10/24/2001	CN1073557C Vitamin-D amide derivatives
10/24/2001	CN1073446C Superfine cordyceps sinensis powder and its prep.
10/23/2001	US6307092 Potent ocular hypotensives and are particularly suited for the management of glaucoma.
10/23/2001	US6307089 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
10/23/2001	US6307049 Useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth.
10/23/2001	US6306900 Enteric coated pharmaceutical compositions
10/23/2001	US6306897 Calanolides for inhibiting BTK
10/23/2001	US6306895 Substituted oxygen alicyclic compounds, including methods for synthesis thereof
10/23/2001	US6306887 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
10/23/2001	US6306886 Solid polymorph anticoagulants
10/23/2001	US6306879 Isotonic glucose solution
10/23/2001	US6306876 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives
10/23/2001	US6306863 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
10/23/2001	US6306840 Cell adhesion inhibitors
10/23/2001	US6306651 Bone marrow hematopoietic stem cell; for use in prevention of graft versus host disease
10/23/2001	US6306405 Use of microparticles combined with submicron oil-in-water emulsions
10/23/2001	US6306404 As adjuvant for vaccines
10/23/2001	US6306401 Genetically-engineered sindbis virus with modified E2 Glycoprotein and altered host-range phenotype
10/23/2001	US6306398 Delipidating plant powder by extraction of powder with a solution containing organic solvent; separating powder from organic solvent; extracting delipidated powder with solvent or phosphate buffered saline; separation to obtain retentate
10/23/2001	US6306395 Fas antigen derivatives
10/23/2001	CA2302963C Soft gelatin capsule manufacture
10/23/2001	CA2236368C Sublingual and buccal administration of selegiline
10/23/2001	CA2223817C Compositions for the treatment of rheumatoid-based arthritic diseases
10/23/2001	CA2079342C Multi-functional pharmaceutical compounds and methods of use
10/23/2001	CA2040058C Alpha-mannosidase and fucosidase inhibitors
10/23/2001	CA2035499C Substituted triazolopyridazines
10/23/2001	CA1341308C Vaccines against avian herpes viruses
10/23/2001	CA1341307C Nucleotide sequences of avian herpes viruses
10/18/2001	WO2001077338A2 Human protein kinases and protein kinase-like enzymes
10/18/2001	WO2001077326A1 Novel g protein-coupled receptor protein and dna thereof
10/18/2001	WO2001077299A2 A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
10/18/2001	WO2001077181A2 Anti-rhesus d monoclonal antibodies
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077169A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077147A2 New bromodomain protein
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077104A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/18/2001	WO2001077089A1 New neurokinin antagonists for use as medicaments
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001076644A2 Lipid-based systems for targeting diagnostic agents
10/18/2001	WO2001076639A2 Chemically-modified myelopoietin conjugates
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076628A1 Chlamydial glycolipid vaccines
10/18/2001	WO2001076626A2 Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
10/18/2001	WO2001076625A1 Iscom polypeptide delivery system
10/18/2001	WO2001076623A1 Iscom polypeptide delivery system for helicobacter pylori antigens
10/18/2001	WO2001076622A2 Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof
10/18/2001	WO2001076616A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	WO2001076615A2 Cxcr4 agonist treatment of hematopoietic cells
10/18/2001	WO2001076606A2 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
10/18/2001	WO2001076600A2 Inhibition of cytokine generation
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076561A2 Pharmaceutical compositions
10/18/2001	WO2001076556A2 Lipid-based drug delivery systems against parasitic infections
10/18/2001	WO2001076555A2 Lipid-based drug delivery systems for topical application
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001026683A3 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
10/18/2001	WO2001021201A3 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
10/18/2001	WO2001021199B1 Highly efficient dendritic cell-targeted dna-vaccination
10/18/2001	WO2001020004A3 Protein phosphatase and kinase proteins
10/18/2001	WO2000073460A3 Modified cytokine for its stabilisation
10/18/2001	WO2000069898A8 Molecular interactions in allergy cells
10/18/2001	WO2000051580A3 Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
10/18/2001	US20010031895 Intermediate p-cyclopropanoyl cumene compounds and derivatives, optionally having a 3-hydroxy group; 1-(benzoylalkyl)-4-(diphenylmethoxy)-piperidine compounds and 1-(a-hydroxybenzylalkyl)-4-(diphenylalkenyl)-piperidines
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031766 Prostaglandin receptor ligands
10/18/2001	US20010031763 Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents
10/18/2001	US20010031741 Methods for treatment of lysosomal storage diseases
10/18/2001	US20010031730 Method for treatment of glutamate related disorders
10/18/2001	US20010031285 Interleukin-4 production inhibitors
10/18/2001	US20010031266 Mixture of a sialic acid binding compound and antigens
10/18/2001	US20010031265 Soaking in solution; then culturing
10/18/2001	US20010031262 Synthetic polymeric carrier; antiallergens
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406033A1 Anti-d monoclonal antibodies
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405907A1 Cxcr4 agonist treatment of hematopoietic cells
10/18/2001	CA2405806A1 A method to prevent graft rejection using tgf-.beta. to induce t suppressor cells
10/18/2001	CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	CA2405413A1 Inhibition of cytokine generation

1 ... 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 ... 1172